title: Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B).
abstract: OBJECTIVE
  Retrospective evaluation of intermediate-stage hepatocellular carcinoma (HCC) patient survival after undergoing chemoembolization based on the Child-Pugh score.
  
  
  METHODS
  Data of intermediate-stage HCC patients undergoing chemoembolization were gathered from 43 centers in Japan. Overall survival rates were compared with Child-Pugh scores.
  
  
  RESULTS
  Of the 329 patients examined in this study, Child-Pugh scores were 5 (CP-5) in 136 patients (41.3%), 6 (CP-6) in 101 patients (30.7%), 7 (CP-7) in 58 (17.7%), 8 (CP-8) in 22 (6.7%), and 9 (CP-9) in 12 (3.6%). Two-year survival rates were 77.5% in CP-5 patients (p = 0.047 vs. CP-6), 65.1% in CP-6 patients (p = 0.038 vs. CP-7), 51.3% in CP-7 patients (p = 0.30 vs. CP-8, p = 0.034 vs. CP-9), 50.3% in CP-8 patients (p = 0.0065 vs. CP-9), and 16.7% in CP-9 patients. Two-year survival rates were 77.2% in 139 patients meeting the 4 tumors of 7 cm criterion with Child-Pugh class A (B1) (p < 0.0001 vs. B2), 59.5% in 178 patients other than B1 and B3 (B2) (p = 0.0014 vs. B3), and 16.7% in 12 patients with Child-Pugh score 9 (B3).
  
  
  CONCLUSIONS
  The Child-Pugh score is a useful prognostic factor to stratify intermediate-stage HCC patients.
authors.affiliation: Department of Interventional Radiology, School of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan, yama@clin.medic.mie-u.ac.jp.
authors.forename: Koichiro
authors.initials: K
authors.lastname: Yamakado
authors.forename: Shiro
authors.initials: S
authors.lastname: Miyayama
authors.forename: Shozo
authors.initials: S
authors.lastname: Hirota
authors.forename: Kimiyoshi
authors.initials: K
authors.lastname: Mizunuma
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakamura
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Inaba
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Norifumi
authors.initials: N
authors.lastname: Nishida
authors.forename: Takeshi
authors.initials: T
authors.lastname: Aramaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Anai
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kora
authors.forename: Shigeo
authors.initials: S
authors.lastname: Oikawa
authors.forename: Ken
authors.initials: K
authors.lastname: Watanabe
authors.forename: Taku
authors.initials: T
authors.lastname: Yasumoto
authors.forename: Kinya
authors.initials: K
authors.lastname: Furuichi
authors.forename: Masato
authors.initials: M
authors.lastname: Yamaguchi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000473:pathology* / Q000628:therapy; D016461:Chemoembolization, Therapeutic / Q000379:methods; D005260:Female; D006801:Humans; D007564:Japan; D008099:Liver / Q000000981:diagnostic imaging / Q000473:pathology; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000473:pathology* / Q000628:therapy; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014057:Tomography, X-Ray Computed / Q000379:methods; D014463:Ultrasonography